There is light at the end of the tunnel.

Novo Nordisk (NYSE:NVO) has introduced the tablet form of its blockbuster obesity treatment Wegovy in the United Arab ...

Novo's approach to global launches will be guided by patient demand and the strength of healthcare and telehealth ...

Novo Nordisk (CPSE:NOVO B) has launched the Wegovy pill in the UAE, the first country outside the U.S. to offer this oral obesity treatment. Regulators in the EU have issued positive opinions ...

A launch in the United Arab Emirates comes as Novo works to recover ground in the weight loss drug market against rival Eli ...

Novo hiked its 2026 full-year guidance on the back of increased expectations for GLP-1 product sales, saying it now expects ...

Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich.

Novo Nordisk's Wegovy weight-loss pill has been approved for use in the United Arab Emirates.

Bollinger Bands Trading Strategies: How to Read Volatility, Identify Market Regimes, and Trade with a Statistical Edge Novo Nordisk's 2025 correction has brought the stock near a major long-term ...

Novo Nordisk (NVO) surged 25% on Ozempic/Wegovy pill launches, FDA approvals, and low valuation. See here for more details.